Standout Papers

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients Wi... 2008 2026 2014 2020 579
  1. A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease (2008)
    William J. Sandborn, Brian G. Feagan et al. Gastroenterology

Immediate Impact

14 from Science/Nature 59 standout
Sub-graph 1 of 18

Citing Papers

Refining the impact of genetic evidence on clinical success
2024 StandoutNature
Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study
2022 Standout
7 intermediate papers

Works of Mark R. Fleisher being referenced

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
2008 Standout

Author Peers

Author Last Decade Papers Cites
Mark R. Fleisher 662 215 423 511 17 1.2k
Cornelia Tillack 846 324 683 479 33 1.5k
Johannes Stallhofer 627 176 566 357 28 1.2k
Pavol Papay 623 320 306 568 36 1.2k
Deborah Woodworth 1113 331 303 775 36 1.4k
B. Tait 438 224 300 155 34 1.1k
Maria Roussomoustakaki 555 556 214 417 27 1.1k
Nathaniel Wisch 751 309 166 503 24 1.2k
C Cuvelier 428 245 334 331 33 1.3k
Natalia Pedersen 789 366 177 592 14 1.2k
Line Nielsen 781 409 520 186 22 1.6k

All Works

Loading papers...

Rankless by CCL
2026